Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110400742 | 11040074 | 2 | F | 20130823 | 20160525 | 20150416 | 20160725 | PER | US-ASTRAZENECA-2013SE65868 | ASTRAZENECA | 24328.00 | DY | F | Y | 56.20000 | KG | 20160726 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110400742 | 11040074 | 1 | SS | LISINOPRIL. | LISINOPRIL | 1 | Oral | U | 0 | TABLET | |||||||||
| 110400742 | 11040074 | 2 | PS | BYETTA | EXENATIDE | 1 | Subcutaneous | NON-AZ PRODUCT, 250 MCG/ ML, 5 MCG, EVERY DAY | A949771A | 21773 | SOLUTION FOR INJECTION IN PRE-FILLED PEN | ||||||||
| 110400742 | 11040074 | 3 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | NON-AZ PRODUCT, 250 MCG/ ML, 5 MCG, EVERY DAY | 21773 | SOLUTION FOR INJECTION IN PRE-FILLED PEN | |||||||||
| 110400742 | 11040074 | 4 | SS | BYETTA | EXENATIDE | 1 | Unknown | NON-AZ PRODUCT, 5 MCG, TWICE DAILY | AM140006 | 21773 | SOLUTION FOR INJECTION IN PRE-FILLED PEN | ||||||||
| 110400742 | 11040074 | 5 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | 21773 | 5 | UG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | BID | |||||||
| 110400742 | 11040074 | 6 | SS | GLYBURIDE. | GLYBURIDE | 1 | Oral | U | 0 | 2.5 | MG | QD | |||||||
| 110400742 | 11040074 | 7 | C | NORVASC | AMLODIPINE BESYLATE | 1 | 0 | 5 | MG | QD | |||||||||
| 110400742 | 11040074 | 8 | C | MULTIVITAMIN | VITAMINS | 1 | 0 | ||||||||||||
| 110400742 | 11040074 | 9 | C | NOVASTATIN | 2 | 0 | 10 | MG | QD | ||||||||||
| 110400742 | 11040074 | 10 | C | LOVASTATIN. | LOVASTATIN | 1 | Oral | 0 | 10 | MG | QD | ||||||||
| 110400742 | 11040074 | 11 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | Oral | 0 | 5 | MG | QD | ||||||||
| 110400742 | 11040074 | 12 | C | VITAMIN D | CHOLECALCIFEROL | 1 | Oral | 0 | 2000 | IU | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 110400742 | 11040074 | 2 | Type 2 diabetes mellitus |
| 110400742 | 11040074 | 3 | Type 2 diabetes mellitus |
| 110400742 | 11040074 | 4 | Type 2 diabetes mellitus |
| 110400742 | 11040074 | 5 | Type 2 diabetes mellitus |
| 110400742 | 11040074 | 10 | Blood cholesterol |
| 110400742 | 11040074 | 12 | Menopausal symptoms |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 110400742 | 11040074 | Blood glucose decreased | |
| 110400742 | 11040074 | Body height decreased | |
| 110400742 | 11040074 | Drug dose omission | |
| 110400742 | 11040074 | Drug hypersensitivity | |
| 110400742 | 11040074 | Glycosylated haemoglobin decreased | |
| 110400742 | 11040074 | Hypoglycaemia | |
| 110400742 | 11040074 | Nervousness | |
| 110400742 | 11040074 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 110400742 | 11040074 | 2 | 20130823 | 20130824 | 0 | |
| 110400742 | 11040074 | 3 | 201408 | 0 | ||
| 110400742 | 11040074 | 4 | 201410 | 0 | ||
| 110400742 | 11040074 | 5 | 2014 | 0 | ||
| 110400742 | 11040074 | 10 | 2012 | 0 |